These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34001679)

  • 1. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
    Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
    Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
    Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
    Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
    Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
    Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased NFATC4 Correlates With Poor Prognosis of AML Through Recruiting Regulatory T Cells.
    Zhao C; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Shi J
    Front Genet; 2020; 11():573124. PubMed ID: 33329712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.
    Wu Z; Guan Q; Han X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Wang X; Zhang H
    Aging (Albany NY); 2021 Oct; 13(19):22947-22962. PubMed ID: 34610582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening of Differential Expression Autophagy Genes Related to the Prognosis of Diffuse Large B-Cell Lymphoma and Establishment of an Autophagy Model].
    Zhang JD; Zhang HM; Lu D; Wang ZN; Chen HR; Lu XC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1101-1108. PubMed ID: 35981368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
    Zhang Z; Zhao C; Yang S; Lu W; Shi J
    Lipids Health Dis; 2024 Jan; 23(1):20. PubMed ID: 38254162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
    Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
    Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
    He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
    J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
    Zhang Q; Zhu Z; Guan J; Zheng C
    Front Oncol; 2022; 12():904614. PubMed ID: 35814424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
    Zheng W; Lin Q; Issah MA; Liao Z; Shen J
    BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
    Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
    Front Immunol; 2021; 12():732006. PubMed ID: 34745101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
    Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
    J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
    Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
    Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
    Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
    Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma.
    Hui X; Li L; Xiong W; Liu Y; Li H; Zhang H; Zhao S; Zhang Y
    Clin Exp Med; 2024 Apr; 24(1):89. PubMed ID: 38683255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.